GSK Buys Affinivax in $3.3B Deal, Nets Two Vaccine Candidates and Novel Technology

By PacConAdmin | May 31, 2022

GSK announced yesterday that it is acquiring Cambridge, Mass.-based biopharma company Affinivax in a $3.3 billion deal, picking up at least two novel pneumococcal vaccine candidates and a promising vaccine technology platform.
Source: Drug Industry Daily

Posted in Drug Industry Daily